Injections, Subcutaneous

• 

  Subject Areas on Research

  • 9 -Tetrahydrocannabinol: a hypotensive effect in rats. 
  • A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A patient with extensive stem cell factor-induced hyperpigmentation. 
  • A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. 
  • AV blockade via selective AV nodal artery injection in a patient. 
  • Abnormal development of blood pressure and growth in rats exposed to perinatal injection stress. 
  • Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. 
  • Acute effects of cocaine on ornithine decarboxylase activity in fetal and neonatal rat heart: evidence for cardiotoxicity. 
  • Acute local subcutaneous VEGF165 injection for augmentation of skin flap viability: efficacy and mechanism. 
  • Adolescent and adult rats respond differently to nicotine and alcohol: motor activity and body temperature. 
  • Adolescent-onset nicotine self-administration modeled in female rats. 
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 
  • An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. 
  • Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. 
  • Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. 
  • Bioavailability of IgG administered by the subcutaneous route. 
  • Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical pearls and strategies to optimize patient outcomes. 
  • Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. 
  • Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital Setting. 
  • Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. 
  • Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. 
  • Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. 
  • Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. 
  • Curious Crosses: Injection-Induced Lesions. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Decreased alcohol consumption by verapamil in alcohol preferring rats. 
  • Delirium with psychotic features possibly associated with mesotherapy. 
  • Depression of murine macrophage accumulation by low-molecular-weight derived from spontaneous mammary carcinomas. 
  • Development of [3H]nicotine binding sites in brain regions of rats exposed to nicotine prenatally via maternal injections or infusions. 
  • Developmental exposure of rats to chlorpyrifos leads to behavioral alterations in adulthood, involving serotonergic mechanisms and resembling animal models of depression. 
  • Does concurrent or prior nicotine exposure interact with neonatal hypoxia to produce cardiac cell damage? 
  • Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. 
  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effects of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase, on nucleic acids and proteins in developing rat brain: critical perinatal periods for regional selectivity. 
  • Effects of caffeine on alcohol consumption and nicotine self-administration in rats. 
  • Effects of sub-chronic in vivo chlorpyrifos exposure on muscarinic receptors and adenylate cyclase of rat striatum. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Elevated lidocaine serum concentration after subcutaneous lidocaine administration using a needle-free device in pediatric patients. 
  • Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 
  • Embolic central retinal artery occlusion after subcutaneous auricular steroid injection. 
  • Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. 
  • Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. 
  • Facial Filler Complications. 
  • Fetal nicotine exposure ablates the ability of postnatal nicotine challenge to release norepinephrine from rat brain regions. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. 
  • Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. 
  • G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. 
  • Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. 
  • Glial cell line-derived neurotrophic factor administration in postnatal life results in motor unit enlargement and continuous synaptic remodeling at the neuromuscular junction. 
  • Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. 
  • Glycemic Variability and Its Impact on Quality of Life in Adults With Type 1 Diabetes. 
  • Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. 
  • Histopathological assessment of triphenyl phosphite neurotoxicity in the hen. 
  • Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. 
  • Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. 
  • Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats. 
  • Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. 
  • Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. 
  • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. 
  • Impact of leuprolide acetate on the response to follicular stimulation for in vitro fertilization in patients with normal basal gonadotropin levels. 
  • Impaired morphological development of the dorsal cochlear nucleus in hamsters treated postnatally with alpha-difluoromethylornithine. 
  • In utero exposure to nicotine and chlorpyrifos alone, and in combination produces persistent sensorimotor deficits and Purkinje neuron loss in the cerebellum of adult offspring rats. 
  • In vivo 31P nuclear magnetic resonance studies on the absorption of triphenyl phosphite and tri-o-cresyl phosphate following subcutaneous administration in hens. 
  • In-hospital management of type 2 diabetes mellitus. 
  • Increased expression of glial fibrillary acidic protein in cerebellum and hippocampus: differential effects on neonatal brain regional acetylcholinesterase following maternal exposure to combined chlorpyrifos and nicotine. 
  • Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. 
  • Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. 
  • Inhibition and recovery of maternal and fetal cholinesterase enzyme activity following a single cutaneous dose of methyl parathion and diazinon, alone and in combination, in pregnant rats. 
  • Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. 
  • Interaction of nicotinic and histamine H(3) systems in the radial-arm maze repeated acquisition task. 
  • Intermittent and continuous cocaine administration: residual behavioral states during withdrawal. 
  • Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA. 
  • Intrathymic injection of donor alloantigens induces donor-specific vascularized allograft tolerance without immunosuppression. 
  • Ischemia contributes to adverse effects of cocaine on brain development: suppression of ornithine decarboxylase activity in neonatal rat. 
  • JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. 
  • Lidocaine toxicity after subcutaneous infiltration in children undergoing cardiac catheterization. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. 
  • Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 
  • Mammary gland morphology in Sprague-Dawley rats following treatment with an organochlorine mixture in utero and neonatal genistein. 
  • Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. 
  • Metabolic behavior of C3 in normal, C4-deficient (C4D) and cortisone-treated guinea pigs. 
  • Minidose heparin therapy for vasculitis of atrophie blanche. 
  • Neurotoxicity of glycidamide, an acrylamide metabolite, following intraperitoneal injections in rats. 
  • Neurotoxicity resulting from coexposure to pyridostigmine bromide, deet, and permethrin: implications of Gulf War chemical exposures. 
  • Nicotine-alcohol interactions and cognitive function in rats. 
  • One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. 
  • Organ distribution of Corynebacterium parvum labeled with iodine-125. 
  • Pasireotide for postoperative pancreatic fistula. 
  • Pathogenesis of a transplanted canine lymphocytic leukemia. 
  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. 
  • Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. 
  • Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. 
  • Persistent behavioral alterations in rats neonatally exposed to low doses of the organophosphate pesticide, parathion. 
  • Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. 
  • Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. 
  • Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. 
  • Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. 
  • Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. 
  • Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402. 
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. 
  • Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. 
  • Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. 
  • Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. 
  • Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. 
  • Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. 
  • Pursuing progress in acute coronary syndromes. 
  • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 
  • Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. 
  • Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. 
  • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. 
  • Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. 
  • Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. 
  • Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. 
  • Relationship between nociceptor activity, peripheral edema, spinal microglial activation and long-term hyperalgesia induced by formalin. 
  • Reversal of systemic toxic effects of scopolamine with physostigmine salicylate. 
  • Review of Periorbital and Upper Face: Pertinent Anatomy, Aging, Injection Techniques, Prevention, and Management of Complications of Facial Fillers. 
  • Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. 
  • Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. 
  • Risking health to avoid injections: preferences of Canadians with type 2 diabetes. 
  • Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Short-term adolescent nicotine exposure in rats elicits immediate and delayed deficits in T-lymphocyte function: critical periods, patterns of exposure, dose thresholds. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Simultaneous reorganization in thalamocortical ensembles evolves over several hours after perioral capsaicin injections. 
  • Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. 
  • Spatial memory retention is enhanced by acute and continuous estradiol replacement. 
  • Specificity of cognitive impairment from Pfiesteria piscicida exposure in rats: attention and visual function versus behavioral plasticity. 
  • Standardization of the single-breath diffusing capacity in a multicenter clinical trial. 
  • Structure-activity studies of 2,3,4,4a,5,9b-hexahydroindeno[1,2-c]pyridines as antispermatogenic agents for male contraception. 
  • Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. 
  • Subcutaneous administration of nimodipine improves bioavailability in rabbits. 
  • Subcutaneous bupivacaine infiltration and postoperative pain perception after percutaneous nephrolithotomy. 
  • Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. 
  • Subcutaneous interferon alfa for the treatment of cutaneous pseudolymphoma. 
  • Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). 
  • Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity? 
  • Sumatriptan-induced stroke in sagittal sinus thrombosis. 
  • Superoxide dismutase mimic, MnTE-2-PyP(5+) ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum. 
  • Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). 
  • TRPC6 enhances angiotensin II-induced albuminuria. 
  • Technosphere insulin: inhaled prandial insulin. 
  • The effect of intrathecal neuropeptide Y on the flexor reflex in rats after carrageenan-induced inflammation. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The subchronic effects of the TRH analog TA-0910 and bromocriptine on alcohol preference in alcohol-preferring rats: development of tolerance and cross-tolerance. 
  • The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. 
  • The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. 
  • Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. 
  • Transient postnatal elevation of norepinephrine content and turnover in brain regions of rats exposed to terbutaline prenatally: evidence for autoregulation of noradrenergic development? 
  • Treatment of HCV infection by targeting microRNA. 
  • Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. 
  • Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. 
  • Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. 
  • Treatment of palatal myoclonus with sumatriptan. 
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. 
  • Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. 
  • Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. 
  • Tumor resistance in rats immunized to fetal tissues. 
  • Type III Hypersensitivity Reaction to Subcutaneous Insulin Preparations in a Type 1 Diabetic. 
  • Use of automated bolus advisors may improve adherence to multiple daily insulin injection therapy. 
  • Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase. 
  • alpha-Melanocyte-stimulating hormone-induced eruptive nevi. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery
  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology